Assays Featured Articles

  1. Dr. Bobby Gaspar On Manufacturing, Commercialization Challenges 2/22/2021

    Orchard Therapeutics CEO Dr. Bobby Gaspar, M.D., Ph.D. is one of only a handful of gene therapy leaders to see the light of market-approved therapy. Here, he offers advice for those seeing manufacturing, regulatory, and reimbursement challenges for the first time.

  2. Single Molecule Measurement: Best Practices In Biomarker Detection 1/7/2015

    By Mark Roskey, Vice President and General Manager, Applications and Reagents 

    The human genome encodes thousands of secreted proteins, each of which is an actor in the delicate biochemical balance of diagnostics. Even a slight change in any one of these proteins can mean the difference between sickness and health. Such a change also provides a critical window into the body and helps to direct diagnosis and treatment, however, the vast majority of secreted proteins are present in concentrations well below what conventional technologies can measure, and their role in human health is poorly understood. Researchers have continued to seek ways to detect and diagnose earlier and more accurately through protein detection, and have been unsuccessful at doing so – until now.

  3. How Do I Get My Compound Into Phase I? 4/2/2014

    The primary challenge for pharmaceutical and biotechnology companies in developing their drugs is to carefully assess the relationship between efficacy and toxicity prior to entering into human clinical trials. By Dr. Scott E. Boley and Greg Ruppert

  4. Hamilton Robotics Launches Highly Flexible PCR Setup Workstation 3/18/2013

    Hamilton Robotics introduces the PCR setup STARlet, the first automated liquid handling system flexible enough to accommodate any DNA amplification reagent kit, from simple setups and small budgets to highly demanding workflows.

  5. BioReliance Acquires Rights To Big Blue Colonies And Cell Lines From Agilent 3/7/2013

    Sigma-Aldrich Corporation recently announced that BioReliance, the biologics and early development services business under SAFC, has signed an agreement to acquire the colonies required for the Big Blue transgenic rodent mutation (TRM) assay and to obtain a license to its associated trademark from Agilent Technologies.

  6. Dako Receives FDA Approval For Fast, Accurate, Nontoxic FISH Assay For Cancer Diagnostics 2/15/2013

    Dako, an Agilent Technologies Company, today introduced IQISH technology in the United States. The technology will reduce the turnaround time for cancer evaluation from two days to three and a half hours.

  7. Pittcon 2013 Conference Tackles Life Sciences Challenges, Novel Research 2/7/2013

    Pittcon has always been the premiere venue for companies to launch new products and for scientists to present their latest research to a global audience.

  8. Automated, High Throughput, HTRF®-Based Detection Of Histone Methyltransferase And Demethylase Enzyme Activity 1/30/2013

    The study of modifications which can affect the transcriptional state of DNA at the chromatin level, otherwise known as epigenetics, has seen increased emphasis in recent years. The alterations that have currently been described include, but are not limited to, acetyl- and deacetylation, methyl- and demethylation, ubiquitylation, and phosphorylation.

  9. Epic Sciences Awarded A Phase II SBIR Contract From NCI/NIH To Develop A Lung Cancer Diagnostic Blood Test 1/25/2013

    Epic Sciences, Inc., ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products.

  10. Hamilton Robotics Builds Affymetrix’ CytoScan Automated Target Preparation Solution On Microlab NIMBUS 1/14/2013

    Hamilton Robotics has announced that the soon-to-launch CytoScan Automated Target Preparation Solution from Affymetrix, Inc. is built on the customizable Microlab® NIMBUS 96 workstation from Hamilton Robotics. The Affymetrix NIMBUS Target Preparation Instrument automates target preparation for the CytoScan Cytogenetics Solution, which offers the broadest coverage and highest performance for detecting human chromosomal aberrations.